Switch to:
Also traded in: Germany, Hongkong

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
OTCPK:CSWYY's Cash-to-Debt is ranked higher than
94% of the 719 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. OTCPK:CSWYY: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:CSWYY' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.58  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.89
OTCPK:CSWYY's Equity-to-Asset is ranked higher than
93% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. OTCPK:CSWYY: 0.89 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:CSWYY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.77  Med: 0.83 Max: 0.89
Current: 0.89
0.77
0.89
Interest Coverage 8500.84
OTCPK:CSWYY's Interest Coverage is ranked higher than
62% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.29 vs. OTCPK:CSWYY: 8500.84 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:CSWYY' s Interest Coverage Range Over the Past 10 Years
Min: 44.82  Med: No Debt Max: 11442.1
Current: 8500.84
44.82
11442.1
Piotroski F-Score: 6
Altman Z-Score: 6.46
Beneish M-Score: -0.73
WACC vs ROIC
4.26%
19.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 29.02
OTCPK:CSWYY's Operating Margin % is ranked higher than
92% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.86 vs. OTCPK:CSWYY: 29.02 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:CSWYY' s Operating Margin % Range Over the Past 10 Years
Min: 29.02  Med: 35.93 Max: 48.66
Current: 29.02
29.02
48.66
Net Margin % 29.24
OTCPK:CSWYY's Net Margin % is ranked higher than
95% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. OTCPK:CSWYY: 29.24 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:CSWYY' s Net Margin % Range Over the Past 10 Years
Min: 29.24  Med: 35.05 Max: 46.98
Current: 29.24
29.24
46.98
ROE % 10.25
OTCPK:CSWYY's ROE % is ranked higher than
63% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. OTCPK:CSWYY: 10.25 )
Ranked among companies with meaningful ROE % only.
OTCPK:CSWYY' s ROE % Range Over the Past 10 Years
Min: 10.25  Med: 18.48 Max: 31.64
Current: 10.25
10.25
31.64
ROA % 8.98
OTCPK:CSWYY's ROA % is ranked higher than
75% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.48 vs. OTCPK:CSWYY: 8.98 )
Ranked among companies with meaningful ROA % only.
OTCPK:CSWYY' s ROA % Range Over the Past 10 Years
Min: 8.98  Med: 15.94 Max: 26.99
Current: 8.98
8.98
26.99
ROC (Joel Greenblatt) % 32.08
OTCPK:CSWYY's ROC (Joel Greenblatt) % is ranked higher than
74% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.44 vs. OTCPK:CSWYY: 32.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:CSWYY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 32.08  Med: 102.65 Max: 162.53
Current: 32.08
32.08
162.53
3-Year Revenue Growth Rate -2.30
OTCPK:CSWYY's 3-Year Revenue Growth Rate is ranked lower than
75% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. OTCPK:CSWYY: -2.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:CSWYY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.3  Med: 9.75 Max: 30.5
Current: -2.3
-2.3
30.5
3-Year EBITDA Growth Rate 1.90
OTCPK:CSWYY's 3-Year EBITDA Growth Rate is ranked lower than
65% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.70 vs. OTCPK:CSWYY: 1.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:CSWYY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0.1  Med: 10 Max: 42.3
Current: 1.9
0.1
42.3
3-Year EPS without NRI Growth Rate -0.40
OTCPK:CSWYY's 3-Year EPS without NRI Growth Rate is ranked lower than
61% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. OTCPK:CSWYY: -0.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:CSWYY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -2.9  Med: 14.35 Max: 38.5
Current: -0.4
-2.9
38.5
GuruFocus has detected 5 Warning Signs with China Shineway Pharmaceutical Group Ltd $OTCPK:CSWYY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:CSWYY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with CSWYY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:OTCPK:NPPNY, NAS:DEPO, NAS:MNTA, OTCPK:TWMJF, NYSE:LCI, NYSE:DPLO, NAS:HRTX, NAS:SGYP, NAS:IPXL, OTCPK:GNMLF, OTCPK:KHTRF, OTCPK:EVTCY, NAS:FLXN, NAS:AMPH, NAS:EGRX, OTCPK:APHQF, OTCPK:ACBFF, NAS:LBIO, NAS:INNL, NAS:SCLN » details
Traded in other countries:C1S.Germany, 02877.Hongkong,
China Shineway Pharmaceutical Group Ltd through its subsidiaries is engaged in research & development, manufacture and trading of Chinese pharmaceutical products. It products portfolio includes; Injections, Soft capsules, Granules and others.

China Shineway Pharmaceutical Group principally involves in the development, manufacture and sales of modern Chinese medicines. Presently, It is the largest manufacturer of Qing Kai Ling Injection, Shen Mai Injection, and Wu Fu Xin Nao Qing Soft Capsule.

Ratios

vs
industry
vs
history
PE Ratio 10.86
CSWYY's PE Ratio is ranked higher than
87% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.50 vs. CSWYY: 10.86 )
Ranked among companies with meaningful PE Ratio only.
CSWYY' s PE Ratio Range Over the Past 10 Years
Min: 4.64  Med: 11.44 Max: 26.09
Current: 10.86
4.64
26.09
PE Ratio without NRI 10.86
CSWYY's PE Ratio without NRI is ranked higher than
87% of the 581 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.49 vs. CSWYY: 10.86 )
Ranked among companies with meaningful PE Ratio without NRI only.
CSWYY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.64  Med: 11.44 Max: 26.09
Current: 10.86
4.64
26.09
Price-to-Owner-Earnings 8.98
CSWYY's Price-to-Owner-Earnings is ranked higher than
90% of the 296 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.92 vs. CSWYY: 8.98 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CSWYY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.12  Med: 15.05 Max: 37.11
Current: 8.98
8.12
37.11
PB Ratio 1.11
CSWYY's PB Ratio is ranked higher than
85% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.93 vs. CSWYY: 1.11 )
Ranked among companies with meaningful PB Ratio only.
CSWYY' s PB Ratio Range Over the Past 10 Years
Min: 1.01  Med: 2.08 Max: 7.37
Current: 1.11
1.01
7.37
PS Ratio 2.87
CSWYY's PS Ratio is ranked lower than
51% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. CSWYY: 2.87 )
Ranked among companies with meaningful PS Ratio only.
CSWYY' s PS Ratio Range Over the Past 10 Years
Min: 2.24  Med: 4.01 Max: 12.29
Current: 2.87
2.24
12.29
Price-to-Free-Cash-Flow 9.57
CSWYY's Price-to-Free-Cash-Flow is ranked higher than
84% of the 228 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.42 vs. CSWYY: 9.57 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CSWYY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.32  Med: 16.67 Max: 107.18
Current: 9.57
7.32
107.18
Price-to-Operating-Cash-Flow 7.93
CSWYY's Price-to-Operating-Cash-Flow is ranked higher than
81% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.18 vs. CSWYY: 7.93 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CSWYY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.64  Med: 12.28 Max: 33.58
Current: 7.93
5.64
33.58
EV-to-EBIT 5.11
CSWYY's EV-to-EBIT is ranked higher than
96% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. CSWYY: 5.11 )
Ranked among companies with meaningful EV-to-EBIT only.
CSWYY' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.6  Med: 7.1 Max: 24.9
Current: 5.11
1.6
24.9
EV-to-EBITDA 5.11
CSWYY's EV-to-EBITDA is ranked higher than
94% of the 573 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.30 vs. CSWYY: 5.11 )
Ranked among companies with meaningful EV-to-EBITDA only.
CSWYY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.5  Med: 6.4 Max: 23.4
Current: 5.11
1.5
23.4
PEG Ratio 22.25
CSWYY's PEG Ratio is ranked lower than
95% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.79 vs. CSWYY: 22.25 )
Ranked among companies with meaningful PEG Ratio only.
CSWYY' s PEG Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.88 Max: 28.57
Current: 22.25
0.26
28.57
Shiller PE Ratio 9.05
CSWYY's Shiller PE Ratio is ranked higher than
95% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.64 vs. CSWYY: 9.05 )
Ranked among companies with meaningful Shiller PE Ratio only.
CSWYY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.16  Med: 11.6 Max: 18.29
Current: 9.05
8.16
18.29
Current Ratio 7.03
CSWYY's Current Ratio is ranked higher than
87% of the 614 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. CSWYY: 7.03 )
Ranked among companies with meaningful Current Ratio only.
CSWYY' s Current Ratio Range Over the Past 10 Years
Min: 3.2  Med: 5.03 Max: 10.36
Current: 7.03
3.2
10.36
Quick Ratio 6.45
CSWYY's Quick Ratio is ranked higher than
87% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.73 vs. CSWYY: 6.45 )
Ranked among companies with meaningful Quick Ratio only.
CSWYY' s Quick Ratio Range Over the Past 10 Years
Min: 3.01  Med: 4.71 Max: 10.23
Current: 6.45
3.01
10.23
Days Inventory 185.15
CSWYY's Days Inventory is ranked lower than
78% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. CSWYY: 185.15 )
Ranked among companies with meaningful Days Inventory only.
CSWYY' s Days Inventory Range Over the Past 10 Years
Min: 53.06  Med: 105.79 Max: 167.98
Current: 185.15
53.06
167.98
Days Sales Outstanding 5.73
CSWYY's Days Sales Outstanding is ranked higher than
96% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.23 vs. CSWYY: 5.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
CSWYY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.25  Med: 2.6 Max: 76.83
Current: 5.73
1.25
76.83
Days Payable 96.16
CSWYY's Days Payable is ranked higher than
65% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. CSWYY: 96.16 )
Ranked among companies with meaningful Days Payable only.
CSWYY' s Days Payable Range Over the Past 10 Years
Min: 64.87  Med: 114.98 Max: 180.59
Current: 96.16
64.87
180.59

Buy Back

vs
industry
vs
history
3-Year Dividend Growth Rate -1.10
CSWYY's 3-Year Dividend Growth Rate is ranked lower than
69% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.10 vs. CSWYY: -1.10 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
CSWYY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3.6 Max: 27.6
Current: -1.1
0
27.6
5-Year Yield-on-Cost % 1.60
CSWYY's 5-Year Yield-on-Cost % is ranked higher than
70% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.91 vs. CSWYY: 1.60 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
CSWYY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.94  Med: 2.57 Max: 7.89
Current: 1.6
0.94
7.89

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.67
CSWYY's Price-to-Net-Cash is ranked higher than
89% of the 209 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.69 vs. CSWYY: 2.67 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CSWYY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.46  Med: 4.66 Max: 11.17
Current: 2.67
2.46
11.17
Price-to-Net-Current-Asset-Value 1.91
CSWYY's Price-to-Net-Current-Asset-Value is ranked higher than
91% of the 486 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. CSWYY: 1.91 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CSWYY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.85  Med: 3.16 Max: 8.51
Current: 1.91
1.85
8.51
Price-to-Tangible-Book 1.24
CSWYY's Price-to-Tangible-Book is ranked higher than
84% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.52 vs. CSWYY: 1.24 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CSWYY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.22  Med: 2.09 Max: 6.13
Current: 1.24
1.22
6.13
Price-to-Graham-Number 0.78
CSWYY's Price-to-Graham-Number is ranked higher than
89% of the 423 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.21 vs. CSWYY: 0.78 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CSWYY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.77  Med: 1.02 Max: 2.45
Current: 0.78
0.77
2.45
Earnings Yield (Greenblatt) % 19.57
CSWYY's Earnings Yield (Greenblatt) % is ranked higher than
97% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. CSWYY: 19.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CSWYY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4  Med: 14.1 Max: 62.7
Current: 19.57
4
62.7
Forward Rate of Return (Yacktman) % 6.31
CSWYY's Forward Rate of Return (Yacktman) % is ranked lower than
57% of the 364 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.76 vs. CSWYY: 6.31 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CSWYY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 6.4  Med: 19.75 Max: 37.1
Current: 6.31
6.4
37.1

More Statistics

Revenue (TTM) (Mil) $288.0
EPS (TTM) $ 2.03
Beta0.20
Short Percentage of Float0.00%
52-Week Range $21.84 - 24.03
Shares Outstanding (Mil)41.35

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)